Street Calls of the Week
Elena Ridloff, Chief Financial Officer and Head of Corp. Dev. at Sionna Therapeutics, Inc. (NASDAQ:SION), sold 9,584 shares of common stock in two separate transactions, according to a Form 4 filing with the Securities and Exchange Commission. The sales, which totaled $240441, occurred on August 29 and September 2, 2025, with prices ranging from $25.08 to $25.18. The transactions come as SION trades near its 52-week high of $26.50, having surged 76% over the past six months. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value.
On August 29, Ridloff sold 748 shares at a weighted average price of $25.18. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.34. Following this transaction, Ridloff directly owns 47,368 shares of Sionna Therapeutics .
The second sale, which took place on September 2, involved 8,836 shares at a weighted average price of $25.08. The price range for these shares was $25.00 to $25.30. Following this transaction, Ridloff directly owns 38,532 shares of Sionna Therapeutics.
The sales were executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on May 20, 2025. InvestingPro data shows the company maintains a GREAT financial health score, with 10+ additional insights available to subscribers.
In other recent news, Sionna Therapeutics has initiated a Phase 1 trial for its novel cystic fibrosis treatment combinations, dosing the first subjects to evaluate safety, tolerability, and pharmacokinetics. The trial involves SION-451, an NBD1 stabilizer, in combination with SION-2222 and SION-109. Guggenheim has reiterated its Buy rating for Sionna Therapeutics, maintaining a $45 price target, following positive topline Phase I safety and pharmacokinetic data. The company plans to advance its NBD1 stabilizers, SION-719 and SION-451, into further clinical development.
RBC Capital has initiated coverage on Sionna Therapeutics with a Sector Perform rating and a $22 price target, noting the potential of its CFTR modulators in the cystic fibrosis space. Sionna also presented preclinical data at a European conference, demonstrating full correction of CFTR protein function in CF models using its dual combination approach. In corporate developments, Sionna held its Annual Meeting of Stockholders, where all proposed board nominees were elected, and the appointment of its independent registered public accounting firm was ratified. These recent developments highlight Sionna’s progress in advancing its cystic fibrosis treatments and corporate governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.